Clinical Trial Update: Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Humacyte HAV vascular grafts in trauma patients (Phase 2/Phase 3), currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Vascular Injury
• Vascular Trauma

Drugs mentioned

• Humacyte Human Acellular Vessel (HAV) (human acellular vessel)

Snippet

Sponsor: Humacyte, Inc. | Conditions: Trauma, Vascular System Injury | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING